Logo Logo
Switch Language to German

Gaebel, Wolfgang; Zaeske, Harald; Hesse, Klaus; Klingberg, Stefan; Ohmann, Christian; Grebe, Jürgen; Kolbe, Henrike; Icks, Andrea; Schneider, Frank; Backes, Volker; Wolff-Menzler, Claus; Guse, Birgit; Gallinat, Jürgen; Bock, Thomas; Jockers-Scheruebl, Maria-Christiane; Krueger, Timo; Jessen, Frank; Bechdolf, Andreas; Kircher, Tilo; Konrad, Carsten; Falkai, Peter; Schaub, Annette; Rudolph, Matthias; Koellner, Volker; Schmid-Ott, Gerhard; Linden, Michael; Lieberei, Barbara; Stuhlinger, Monika; Sommerfeld, Sebastian; Schumacher, Albrecht; Krenge, Sabine; Gereke, Stephanie; Moenter, Norbert; Navarro-Urena, Alicia; Frosch, Guenter; Kuhlbusch, Franz-Josef; Cleveland, Helen and Riesbeck, Mathias (2020): Promoting stigma coping and empowerment in patients with schizophrenia and depression: results of a cluster-RCT. In: European Archives of Psychiatry and Clinical Neuroscience, Vol. 270, No. 5: pp. 501-511

Full text not available from 'Open Access LMU'.


There is a need for interventions supporting patients with mental health conditions in coping with stigma and discrimination. A psycho-educational group therapy module to promote stigma coping and empowerment (STEM) was developed and tested for efficacy in patients with schizophrenia or depression. 30 clinical centers participated in a cluster-randomized clinical trial, representing a broad spectrum of mental health care settings: in-patient (acute treatment, rehabilitation), out-patient, and day-hospitals. As randomized, patients in the intervention group clusters/centers received an illness-specific eight sessions standard psychoeducational group therapy plus three specific sessions on stigma coping and empowerment ('STEM'). In the control group clusters the same standard psychoeducational group therapy was extended to 11 sessions followed by one booster session in both conditions. In total,N = 462 patients were included in the analysis (N = 117 with schizophrenia spectrum disorders, ICD-10 F2x;N = 345 with depression, ICD-10 F31.3-F31.5, F32-F34, and F43.2). Clinical and stigma-related measures were assessed before and directly after treatment, as well as after 6 weeks, 6 months, and 12 months (M12). Primary outcome was improvement in quality of life (QoL) assessed with the WHO-QOL-BREF between pre-assessment and M12 analyzed by mixed models and adjusted for pre-treatment differences. Overall, QoL and secondary outcome measures (symptoms, functioning, compliance, internalized stigma, self-esteem, empowerment) improved significantly, but there was no significant difference between intervention and control group. The short STEM module has proven its practicability as an add-on in different settings in routine mental health care. The overall increase in empowerment in both, schizophrenia and depression, indicates patients' treatment benefit. However, factors contributing to improvement need to be explored. The study has been registered in the following trial registers. ClinicalTrials.gov:Registration number: NCT01655368. DRKS:Registration number: DRKS00004217.

Actions (login required)

View Item View Item